Denali Therapeutics director Nancy Thornberry sold 11,439 shares in two transactions priced from $22.85 to $23.74 per share on 2026-09-02. She retained 19,686 Denali Therapeutics shares afterward, giving investors the director’s reported remaining ownership following the transactions.
Key Highlights
- The transactions took place on 2 September 2026 and both carried SEC transaction code S.
- Nancy Thornberry’s reported ownership stood at 19,686 Denali Therapeutics shares after the sales.
- The 11,439-share total was divided across two separate transactions.
Denali Therapeutics Inc. (NASDAQ: DNLI) director Nancy Thornberry sold 11,439 shares at prices ranging from $22.85 to $23.74 per share. The reported transactions leave Thornberry with 19,686 shares of Denali Therapeutics.
Two Transactions Recorded on 2 September 2026
The sales occurred on 2 September 2026 and were recorded as two separate transactions. Both entries used SEC transaction code S. Thornberry is identified as a director of Denali Therapeutics. The post-transaction ownership figure was 19,686 shares.
FAQs
Q: How many Denali Therapeutics shares did Nancy Thornberry sell?
A: Nancy Thornberry sold 11,439 Denali Therapeutics shares across two transactions on 2 September 2026. Prices ranged from $22.85 to $23.74 per share.
Q: What was Nancy Thornberry’s Denali Therapeutics shareholding after the sale?
A: Thornberry owned 19,686 Denali Therapeutics shares after the transactions. That figure represents her reported ownership following the sales in the filing.
Q: At what prices did the Denali Therapeutics director sell shares?
A: The reported Denali Therapeutics transactions were priced between $22.85 and $23.74 per share. Both transactions carried SEC transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.